Our top pick for
Building a portfolio
Revance Therapeutics, Inc is a biotechnology business based in the US. Revance Therapeutics shares (RVNC) are listed on the NASDAQ and all prices are listed in US Dollars. Revance Therapeutics employs 470 staff and has a trailing 12-month revenue of around USD$15.3 million.
|52-week range||USD$14.5 - USD$33.64|
|50-day moving average||USD$27.0956|
|200-day moving average||USD$26.773|
|Wall St. target price||USD$37.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.712|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$15.3 million|
|Gross profit TTM||USD$-97,211,000|
|Return on assets TTM||-30.42%|
|Return on equity TTM||-94.06%|
|Market capitalisation||USD$2 billion|
TTM: trailing 12 months
There are currently 3.6 million Revance Therapeutics shares held short by investors – that's known as Revance Therapeutics's "short interest". This figure is 3.7% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting Revance Therapeutics shares can be evaluated.
Revance Therapeutics's "short interest ratio" (SIR) is the quantity of Revance Therapeutics shares currently shorted divided by the average quantity of Revance Therapeutics shares traded daily (recently around 515895.21044993). Revance Therapeutics's SIR currently stands at 6.89. In other words for every 100,000 Revance Therapeutics shares traded daily on the market, roughly 6890 shares are currently held short.
However Revance Therapeutics's short interest can also be evaluated against the total number of Revance Therapeutics shares, or, against the total number of tradable Revance Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Revance Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Revance Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0518% of the tradable shares (for every 100,000 tradable Revance Therapeutics shares, roughly 52 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Revance Therapeutics.
Find out more about how you can short Revance Therapeutics stock.
We're not expecting Revance Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Revance Therapeutics's shares have ranged in value from as little as $14.5 up to $33.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Revance Therapeutics's is 1.2923. This would suggest that Revance Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.